Westlake Village-based MannKind Corp. failed to meet analysts’ expectations in the second quarter of 2022, but the company welcomed new sources of revenue that could make a big difference in the near future. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, had a net loss of $29 million for the…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
